Gregory Branigan, AAN 2021: Impact of Estrogen Therapies on Alzheimer’s Disease Pathways
We were delighted to meet with Gregory Branigan (University of Arizona, AZ, USA) to discuss the impact of estrogen therapies on Alzheimer’s disease pathways.
The abstract entitled: ‘Breast Cancer Therapies Reduce Risk of Alzheimer’s Disease and Dementia: Clinic to Bench Translation’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- What is the rationale for investigating the impact of estrogen modulating therapy (EMT) exposure on the risk of neurodegenerative disease (NDD) in women with breast cancer? (0:19)
- Could you tell us a little about your short study and its findings? (1:46)
- What is known about the molecular mechanisms underlying this observed risk reduction? (2:36)
- What are the wider implications of these findings? (4:06)
- What future studies are planned? (5:08)
Disclosures: Gregory Branigan has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.